ContractLoan and Security Agreement • April 11th, 2013 • Aratana Therapeutics, Inc. • Pharmaceutical preparations • North Carolina
This LOAN AND SECURITY AGREEMENT (the “Agreement”) is entered into as of March 4, 2013, by and between Square 1 Bank (“Bank”) and Aratana Therapeutics, Inc. (“Borrower”).
EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005Exclusive Ip License Agreement • April 11th, 2013 • Aratana Therapeutics, Inc. • Pharmaceutical preparations • New York
This EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005 (this “Agreement”) is entered into as of December 27, 2010 (the “Effective Date”) by and between Aratana Therapeutics Inc., a Delaware corporation having a place of business is 1901 Olathe Boulevard, Kansas City, KS 66103 (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation having a place of business at 5-2 Taketoyo, Aichi 470-2341, Japan (“Licensor”).
API DEVELOPMENT AGREEMENTApi Development Agreement • April 11th, 2013 • Aratana Therapeutics, Inc. • Pharmaceutical preparations • New York
This API DEVELOPMENT AGREEMENT (this “Agreement”) is entered into as of July 12, 2012 (the “Effective Date”) by and between Aratana Therapeutics Inc., a Delaware corporation (“Aratana”) and RaQualia Pharma Inc., a Japanese corporation (“RaQualia”). Aratana and RaQualia are referred to herein individually as a “Party” and collectively as the “Parties”.
EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000007Exclusive Ip License Agreement • April 11th, 2013 • Aratana Therapeutics, Inc. • Pharmaceutical preparations • New York
This EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000007 (this “Agreement”) is entered into as of December 27 2010 (the “Effective Date”) by and between. Aratana Therapeutics Inc., a Delaware corporation having a place of business is 1901 Olathe Boulevard, Kansas City, KS 66103 (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation having a place of business at 5-2 Taketoyo, Aichi 470-2341, Japan (“Licensor”).
KANSAS BIOSCIENCE RESEARCH AND DEVELOPMENT (R&D) VOUCHER PROGRAM GRANT AGREEMENTGrant Agreement • April 11th, 2013 • Aratana Therapeutics, Inc. • Pharmaceutical preparations • Kansas
This Research and Development Voucher Grant Agreement (“Agreement”) dated as March 6, 2012 (the “Effective Date”) is by and between the Kansas Bioscience Authority, 10900 S. Clay Blair Blvd., Olathe, Kansas 66061 (the “KBA”) and Aratana Therapeutics, Inc., 1901 Olathe Blvd., Kansas City, KS 66103 (the “Grantee”), collectively the “Parties.”
RAQUALIA PHARMA, INC. JapanLicense Agreement • April 11th, 2013 • Aratana Therapeutics, Inc. • Pharmaceutical preparations • Tokyo
This letter agreement (“Agreement”) is intended to confirm the mutual understandings and agreements between RAQUALIA PHARMA, INC., a Japanese corporation (“RaQualia”), and ARATANA THERAPEUTICS, INC., a Delaware corporation (“Aratana”), with respect to certain matters pertaining to RQ-00000008. RaQualia and Aratana are referred to herein collectively as the “Parties”.
First Amendment to the Exclusive IP License Agreement for RQ-00000005 between Aratana Therapeutics Inc. and RaQualia Pharma Inc.Exclusive Ip License Agreement • April 11th, 2013 • Aratana Therapeutics, Inc. • Pharmaceutical preparations
This is the First Amendment (“Amendment”) to the Exclusive IP License Agreement for RQ-00000005 dated December 27, 2010 (the “Agreement”) between Aratana Therapeutics Inc., a Delaware corporation (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation (“Licensor”), and is made and entered into between Licensee and Licensor on July 12, 2012 (the “Amendment Effective Date”). Licensee and Licensor are referred to herein individually as a “Party” and collectively as the “Parties”.
SERVICES AGREEMENTServices Agreement • April 11th, 2013 • Aratana Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Services Agreement (the “Agreement”) is dated as of February 28th, 2013 among Aratana Therapeutics, Inc. (the “Company”), MPM Asset Management LLC (“MPM”), and John W. Vander Vort (“Consultant”).
PACIRA PHARMACEUTICALS, INC. and ARATANA THERAPEUTICS, INC. SUPPLY AGREEMENT DATED AS OF DECEMBER 5, 2012Supply Agreement • April 11th, 2013 • Aratana Therapeutics, Inc. • Pharmaceutical preparations • New Jersey
THIS SUPPLY AGREEMENT (this “Agreement”) is made effective as of December 5, 2012 (the “Effective Date”) by and between Pacira Pharmaceuticals, Inc., a California corporation with a principal place of business at 5 Sylvan Way, Parsippany, New Jersey 07054 (“Pacira”) and Aratana Therapeutics, Inc., a Delaware corporation with a place of business at 1901 Olathe Blvd, Kansas City, Kansas 66103 (“Aratana”). Pacira and Aratana are each hereafter referred to individually as a “Party” and together as the “Parties.” Capitalized terms used herein and not otherwise defined herein shall have the meanings set forth in Section 1.
First Amendment to the Exclusive IP License Agreement for RQ-00000007 between Aratana Therapeutics Inc. and RaQualia Pharma Inc.Exclusive Ip License Agreement • April 11th, 2013 • Aratana Therapeutics, Inc. • Pharmaceutical preparations
This is the First Amendment (“Amendment”) to the Exclusive IP License Agreement for RQ-00000007 dated December 27, 2010 (the “Agreement”) between Aratana Therapeutics Inc., a Delaware corporation (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation (“Licensor”), and is made and entered into between Licensee and Licensor on July 12, 2012 (the “Amendment Effective Date”). Licensee and Licensor are referred to herein individually as a “Party” and collectively as the “Parties”.
